The role of socio-behavioral factors in sub-protective tenofovir diphosphate (TFV-DP) levels among YMSM enrolled in two PrEP trials

Citation: 3. Arrington-Sanders R, Wilson CM, Perumean-Chaney SE, Patki A 2nd, Hosek S. The role of socio-behavioral factors in sub-protective tenofovir diphosphate (TFV-DP) levels among YMSM enrolled in two PrEP trials. J Acquir Immune Defic Syndr. 2018 Oct 26. doi: 10.1097/QAI.0000000000001901. PMID 30399038; PMCID: PMC6486465

Access full article:

https://www.ncbi.nlm.nih.gov/pubmed/30399038

BACKGROUND:
Young men who have sex with men (YMSM) experience disparities in HIV acquisition more than any other group. Daily oral pre-exposure prophylaxis (PrEP) with tenofovir/embricitabine (TDF/FTC) has been shown to effectively prevent HIV transmission in YMSM; however, recent studies suggest that young Black men who have sex with men (YBMSM) experience sub-protective levels of tenofovir diphosphate (TFV-DP) more frequently than other groups.

SETTING:
Combined data from Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 110/113, two open label PrEP studies that provided PrEP and evidence-based behavioral interventions to young MSM (YMSM) age 15 to 22 years old.

METHODS:
Bivariate and logistic regression analysis were used to examine sociodemographic and behavioral factors associated with protective TVF-DP levels (defined as ≥700 fmol/punch) in ATN 110/113 data.

RESULTS:
In bivariate analysis, self-identified Black participants, residential displacement due to sexual orientation, low perceived risk, and stigma with the medication were associated with sub-protective levels. Hispanic ethnicity was associated with protective levels. In the final models, Black males were less likely to have sub-protective levels than non-Black males at 4, 8, 12 weeks. Self-reported displacement due to sexual orientation was associated with sub-protective levels while older age was as associated with protective levels.

CONCLUSION:
These findings highlight how future behavioral research and biomedical prevention efforts in YMSM will need to address PrEP disparities that may occur in YBMSM, perception of risk and lack of key supportive housing during this period that may be critical factors that contribute to HIV acquisition.

Categories

CRS
Topics

Clinical Trials

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

Read More